Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC
about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsA novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingDynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.Approaches to modelling the human immune response in transition of candidates from research to development.Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populationsExploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsIn vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis.Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosaIn vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBClinical microdialysis in skin and soft tissues: an update.In the aftermath of the Fusarium keratitis outbreak: What have we learned?Enhancement of the enterocin CRL35 activity by a synthetic peptide derived from the NH2-terminal sequence.In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuisPharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.Effect of gingivitis on azithromycin concentrations in gingival crevicular fluidIn vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeaePharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacodynamic modelling of in vitro activity of tetracycline against a representative, naturally occurring population of porcine Escherichia coli.Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.Improvement of experimental testing and network training conditions with genome-wide microarrays for more accurate predictions of drug gene targets.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of MoleculesIn vitro pharmacodynamic models to determine the effect of antibacterial drugs.Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.Histones from Avian Erythrocytes Exhibit Antibiofilm activity against methicillin-sensitive and methicillin-resistant Staphylococcus aureus.Protein binding: do we ever learn?
P2860
Q21144510-5749AEEC-5706-4A2E-9742-ADBC8BDB091DQ26827380-7220C4CF-3C8D-4037-BC97-AC34A0E7F7F5Q28476705-8BF097AF-0333-4E91-BED4-1D21814DF4E8Q28550711-7FC9DEF2-6256-4AFA-8C68-6B4571C9A4EBQ31029779-85DB60F5-3ECA-4018-B0DD-BFD598005E75Q33661296-D6277819-0564-4F58-A30F-8721F47DE6A5Q33722011-C4528CD9-1080-41E9-B8E2-58BCC48C38FBQ33767602-03485E39-8879-4DB4-8489-C118F3601BACQ33797084-85EDCB04-F6BD-4553-816A-763A28F5277FQ33802909-DBA14CB8-0EA9-45FB-9F30-366BD796C640Q33826426-20EEF07F-C751-4D97-A096-84140FE7AE47Q34150973-EA096B45-8FF7-49AA-A0F0-862DD34A5C20Q34509793-76936DEC-B920-4652-9A5C-8ACA0B624F57Q34591451-D99961F7-1A52-41FC-804D-02D48300933FQ34752069-AB97DC42-D00D-468A-B794-CDE3D3E680F9Q34996611-9EAFEF25-CD0B-4D44-B703-6C5070321743Q35124888-7EC57554-3EF2-4BC9-AE73-0F9D53279800Q35151557-92C5EBDE-C1D9-4EF9-81B4-3C48BA7BEA1BQ35191390-CD1D1521-7AF7-4255-B7ED-6BED7CDB1166Q35635652-74D64D08-7514-4BF0-9707-6F463D72E72BQ35857801-FB64BAD9-C698-433B-B26C-A5216911B4E3Q35879111-CF21CD9B-2325-477E-B1C2-B91F173D1116Q35918653-07B1656A-AEE1-430E-9612-21A17E334328Q36018672-B76F0F91-1BEF-4A27-9D5C-6A4E6B5906BDQ36136318-82868C8F-B81C-4EE7-906D-512992B6A4C3Q36162355-B8E7BD58-DBC5-4028-BC93-3C6D190A04BCQ36310839-99B9A432-F704-494B-B4A1-49E8E648C98CQ36320608-B0BC615F-4AFC-4AD8-8547-ECC211EB32CEQ36482785-54A3A795-A40F-43C0-AD77-6C7B2F2BBE84Q37149078-3AE010F4-21CB-48BC-86D6-4817FC847209Q37247584-3564997D-1046-4421-A68A-57A19CD92298Q37441394-EA823235-12F3-4017-A7CF-7C4BAF1EAC53Q37449679-E26F594D-FE0B-4FC1-9748-4FCA94DB5763Q37548278-699F2A32-B3FB-4D1E-8AF5-E9DF53E4C33DQ37568933-8E1229CA-CA2F-4D79-BFD1-EDE32FEC041CQ37630801-FCF6AB15-E708-4EA5-8B0A-E2129FA58ED1Q37660762-76424BC7-456B-44DB-A87B-AE7ABA820FAFQ37696606-5D80007B-39D0-4156-9A19-3ED1DAC68E46Q37737872-8E7CECDF-6C6C-4170-A4E8-D9FF0A8D9419Q37871252-608A4219-3F13-4C21-9E03-37086E5A75E3
P2860
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@ast
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@en
type
label
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@ast
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@en
prefLabel
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@ast
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@en
P2093
P2860
P1476
Issues in pharmacokinetics and ...... agents: kill curves versus MIC
@en
P2093
Amparo de la Peña
Hartmut Derendorf
Markus Mueller
P2860
P304
P356
10.1128/AAC.48.2.369-377.2004
P407
P577
2004-02-01T00:00:00Z